Johnson & Johnson’s Vaccine Produced Immune Response in Earlier-Stage Study

Vastavam web: Johnson & Johnson’s experimental Covid-19 vaccine induced immune responses in most people who received the shot in a small early-stage trial, and also displayed an acceptable safety profile, according to a study posted online Friday. The findings added more detail to J&J’s announcement earlier this week that the results from the Phase 1/2 trial were positive, and mean the vaccine, one of the leading candidates in development, has taken another step toward proving whether it works safely.

The results supported J&J’s decision to start a larger late-stage study of up to 60,000 people that will provide more definitive evidence of whether the vaccine safely protects people from Covid-19, according to the company. The large Phase 3 study could yield initial results by the end of the year or early 2021. If they are positive, the company said it would seek government authorization of emergency use.